I experienced rapid onset of atopic dermatitis on my thighs and underarms; This rash has since spread across my torso and up my neck over the course of 4 days; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 4 hours post-vacc: headache, fatigue 9 hours post-vacc: headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours.; 14 hours post-vacc: body aches, headache 30 hours post-vacc: all adverse events ceased except slight soreness at injection site (normal).; This is a spontaneous report from a contactable consumer (patient) via COVID-19 Adverse Event Self-Reporting Solution (COVAES). A 28years old (at the age of 28-years-old) non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: EP6955) via an unspecified route, administered in left arm on 24Mar2021 11:00 as dose 2, single for COVID-19 immunization. The patient medical history included, generalized anxiety disorder, post-traumatic stress disorder (PTSD), anxiety and allergy to erythromycin. The patient concomitant medications included prazosin 1mg/day, sertraline 100mg/day within 2 weeks of vaccination. The patient had not received any other vaccines received within 4 weeks prior to vaccination. Prior to vaccination, was the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: EL3248) via an unspecified route, administered in Left Arm on 03Mar2021 at 17:00 as a dose 1, single for COVID-19 immunization. On 24Mar2021 at 15:00 (4 hours after second dose of vaccination), the patient experienced headache, fatigue. After 9 hours she experienced headache, fatigue, fever, chills, minor nausea. Serious chills/shaking lasted 4 hours. After 14 hours, she had body aches, headache. After 30 hours all adverse events ceased except slight soreness at injection site (normal). The patient took Ibuprofen to mitigate fever/aches. On 26Mar2021 at 19:00 (60 hours post-injection of dose2), she experienced rapid onset of atopic dermatitis on her thighs and underarms. This rash had since spread across her torso and up her neck over the course of 4 days (3/26-3/30) and was ongoing. She was seeking care via a dermatologist. Since the vaccination, the patient had not been tested for COVID-19. The adverse event atopic dermatitis on her thighs and underarms resulted to visit doctor or other healthcare professional office/clinic visit. It was unknown if patient received any treatment medications for atopic dermatitis on my thighs and underarms and rash. The patient did not received any treatment medication for resulted events other than soreness at injection site. The outcome of the event atopic dermatitis on her thighs and underarms and Vaccination site pain, this rash has since spread across my torso and up my neck over the course of 4 days was not recovered and the outcome of other events was recovered on unspecified date in 2021. The seriousness of the events was reported as non-serious.   No Follow-up attempts are needed. No further information was expected.